Claims for Patent: 10,213,444

Summary for Patent: 10,213,444

Title:	Composition and method for treating bipolar disorder
Abstract:	Disclosed is a composition suitable for oral administration and capable of treating individuals suffering from unipolar disorder, bipolar disorder and/or bipolar disorder with an unhealthy body weight. The composition comprises a combination therapy of minocycline and acetylsalicylic acid delivered in doses that improve metabolic function and/or exert immune-modulating and/or anti-inflammatory effects. Also disclosed is a method for treating individuals suffering from the indicated disorders.
Inventor(s):	Drevets; Wayne Curtis (Newton, PA), Yates; William Robert (Tulsa, OK), Savitz; Jonathan Bradley (Tulsa, OK), Preskorn; Sheldon H. (Wichita, KS)
Assignee:	Laureate Institute For Brain Research (Tulsa, OK)
Application Number:	15/532,851
Patent Claims:	1. A method for treating bipolar depression in an individual comprising: delivering, as a single drug delivery system, to an individual with bipolar depression a pharmacologically effective amount of a compound capable of inhibiting a COX-1enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain. 2. The method of claim 1, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme. 3. The method of claim 1, wherein said single drug delivery system delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1 enzyme to said individual. 4. The method of claim 1, wherein said method delivers said compound capable of inhibiting a COX-1 enzyme and said compound capable of modulating the release of cytokines from microglial cells in the brain to said individual twice a day. 5. The method of claim 1, wherein said method delivers said compound capable of inhibiting a COX-1 enzyme and said compound capable of modulating the release of cytokines from microglial cells in the brain to said individual once in the morning and once in the evening. 6. The method of claim 1 wherein said compound capable of inhibiting a COX-1 enzyme is selected from the group consisting of: acetylsalicylic acid and naproxen. 7. The method of claim 1, wherein said compound capable of modulating the release of cytokines from microglial cells in the brain is selected from the group consisting of minocycline, adalimumab, certolizumab, pegol, anakinra, rilonacept and canakinumab. 8. A method for treating bipolar depression in an individual comprising: delivering, as a single drug delivery system, to an individual with bipolar depression and a body mass index of greater than 25 a pharmacologically effective amount of a compound capable of inhibiting a COX-1 enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain. 9. The method of claim 8, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme. 10. The method of claim 8, wherein said single drug delivery system delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1 enzyme. 11. A method for treating bipolar depression in a female individual comprising: delivering, as a single drug delivery system, to a female individual with bipolar depression a pharmacologically effective amount of a compound capable of inhibiting a COX-1 enzyme and a pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells in the brain. 12. The method of claim 11, wherein said single drug delivery system delivers from about 0.5 mg/kg of body weight to about 2.0 mg/kg of body weight of said pharmacologically effective amount of said compound capable of inhibiting a COX-1enzyme. 13. The method of claim 11, wherein said pharmacologically effective amount of a compound capable of modulating the release of cytokines from microglial cells delivers from about 1 mg/kg of body weight to about 6 mg/kg of body weight to said individual.

Details for Patent 10,213,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001		2034-12-04
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2034-12-04
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2034-12-04